Ratings by H.C. Wainwright (Ananda Ghosh)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/2/2026 | Structure Therapeutics | GPCR | Maintain | Buy (N/A) |
|
Details | ||
| 2/3/2026 | Skye Bioscience | SKYE | Maintain | Buy (Buy) |
|
Details | ||
| 1/28/2026 | Inventiva SA | IVA | Maintain | Buy (Buy) |
|
Details | ||
| 1/28/2026 | Maze Therapeutics | MAZE | Maintain | Buy (Buy) |
|
Details | ||
| 12/22/2025 | Structure Therapeutics | GPCR | Maintain | Buy (N/A) |
|
Details | ||
| 12/4/2025 | Maze Therapeutics | MAZE | Maintain | Buy (N/A) |
|
Details | ||
| 11/28/2025 | Structure Therapeutics | GPCR | Maintain | Buy (Buy) |
|
Details | ||
| 10/27/2025 | Avidity Biosciences | RNA | Downgrade | Neutral (Buy) |
49.15 (14.82) |
-69.85% | Details | |
| 10/9/2025 | Inventiva SA | IVA | Maintain | Buy (N/A) |
|
Details | ||
| 10/3/2025 | Maze Therapeutics | MAZE | Maintain | Buy (Buy) |
|
Details | ||
| 9/30/2025 | Sykes Enterprises | SYKE | New Coverage | Buy (N/A) |
54.00 (54.00) |
0% | Details | |
| 9/24/2025 | Structure Therapeutics | GPCR | Maintain | Buy (Buy) |
|
Details | ||
| 9/15/2025 | Maze Therapeutics | MAZE | Maintain | Buy (N/A) |
|
Details | ||
| 9/15/2025 | Avidity Biosciences | RNA | Maintain | Buy (N/A) |
|
Details | ||
| 9/12/2025 | Maze Therapeutics | MAZE | Maintain | Buy (N/A) |
|
Details | ||
| 9/3/2025 | Inventiva SA | IVA | New Coverage | Buy (N/A) |
5.26 (6.13) |
16.54% | Details | |
| 8/8/2025 | Structure Therapeutics | GPCR | Maintain | Buy (N/A) |
|
Details | ||
| 6/23/2025 | Structure Therapeutics | GPCR | Maintain | Buy (Buy) |
|
Details | ||
| 6/10/2025 | Avidity Biosciences | RNA | Maintain | Buy (Buy) |
|
Details | ||
| 5/13/2025 | Avidity Biosciences | RNA | Maintain | Buy (N/A) |
|
Details | ||
| 5/12/2025 | Structure Therapeutics | GPCR | Maintain | Buy (N/A) |
|
Details | ||
| 4/22/2025 | Structure Therapeutics | GPCR | Maintain | Buy (Buy) |
|
Details | ||
| 3/18/2025 | Avidity Biosciences | RNA | Maintain | Buy (Buy) |
|
Details | ||
| 12/20/2024 | Structure Therapeutics | GPCR | Maintain | Buy (Buy) |
|
Details | ||
| 12/20/2024 | Avidity Biosciences | RNA | New Coverage | Buy (N/A) |
31.29 (49.15) |
57.08% | Details | |
| 12/4/2024 | Structure Therapeutics | GPCR | New Coverage | Buy (N/A) |
33.25 (57.73) |
73.62% | Details |
